Showing results (161-170 of 176) with videos related to

Sort By:
Pageof 18
Cancers|January 11, 2024
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control StudyMargherita Turinetto, Andrea Ricotti, Claudia Marchetti, et al.
Gynecologic Oncology|March 25, 2023
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trialLucia Musacchio, Margherita Turinetto, Laura Arenare, et al.
Gynecologic Oncology|March 6, 2025
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgeryClaudia Marchetti, Raffaella Ergasti, Filippo Maria Capomacchia, et al.
Gynecologic Oncology|October 9, 2016
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19)Claudia Marchetti, Gabriella Ferrandina, Gennaro Cormio, et al.
JCO Oncology Practice|November 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian CancerClaudia Marchetti, Gwenael Ferron, Olivier Colomban, et al.
Cancer Treatment Reviews|November 8, 2023
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, et al.
International Journal of Radiation Oncology, Biology, Physics|September 10, 2024
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective StudyGabriella Macchia, Donato Pezzulla, Maura Campitelli, et al.
Gynecologic Oncology|November 9, 2019
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcomeSabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2021
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group studySabrina Chiara Cecere, Lucia Musacchio, Michele Bartoletti, et al.
American Journal of Obstetrics and Gynecology|December 24, 2013
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinomaPierluigi Benedetti Panici, Stefano Basile, Maria Giovanna Salerno, et al.
Pageof 18